Report Detail
Global Peptide Cancer Vaccine Market Growth 2019-2024
- RnM2988999 |
- 20 February, 2019 |
- Global |
- 166 Pages |
- LPI(LP Information) |
- Pharma & Healthcare
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
With the ever increasing new cancer cases across the globe and the conventional treatment methods unable to cope up with the challenges posed by the tumor and their immune response evading techniques, cancer immunotherapy brings a ray of hope. Cancer immunotherapy allows the host's immune cells to get sensitized with the tumor-associated antigens which in turn elicits B cell and T cell mediated immune response to target and eliminate tumor cells. This is the underlying principle of cancer immunotherapy.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion in 2025 is about 40%.
According to this study, over the next five years the Peptide Cancer Vaccine market will register a 23.1% CAGR in terms of revenue, the global market size will reach US$ 780 million by 2024, from US$ 280 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Peptide Cancer Vaccine business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Cancer Vaccine market by product type, application, key manufacturers and key regions and countries.
This study considers the Peptide Cancer Vaccine value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Type I
Type II
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
TapImmune
BrightPath Biotherapeutics
Ultimovacs
Sellas
Boston Biomedical
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Immatics
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Peptide Cancer Vaccine consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Peptide Cancer Vaccine market by identifying its various subsegments.
Focuses on the key global Peptide Cancer Vaccine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Peptide Cancer Vaccine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Peptide Cancer Vaccine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Peptide Cancer Vaccine Consumption Market Report
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Peptide Cancer Vaccine Consumption 2014-2024
- 2.1.2 Peptide Cancer Vaccine Consumption CAGR by Region
- 2.2 Peptide Cancer Vaccine Segment by Type
- 2.2.1 Type I
- 2.2.2 Type II
- 2.3 Peptide Cancer Vaccine Consumption by Type
- 2.3.1 Global Peptide Cancer Vaccine Consumption Market Share by Type (2014-2019)
- 2.3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Type (2014-2019)
- 2.3.3 Global Peptide Cancer Vaccine Sale Price by Type (2014-2019)
- 2.4 Peptide Cancer Vaccine Segment by Application
- 2.4.1 Breast Cancer
- 2.4.2 Lung Cancer
- 2.4.3 Melanoma
- 2.4.4 Prostate Cancer
- 2.4.5 Others
- 2.5 Peptide Cancer Vaccine Consumption by Application
- 2.5.1 Global Peptide Cancer Vaccine Consumption Market Share by Application (2014-2019)
- 2.5.2 Global Peptide Cancer Vaccine Value and Market Share by Application (2014-2019)
- 2.5.3 Global Peptide Cancer Vaccine Sale Price by Application (2014-2019)
3 Global Peptide Cancer Vaccine by Players
- 3.1 Global Peptide Cancer Vaccine Sales Market Share by Players
- 3.1.1 Global Peptide Cancer Vaccine Sales by Players (2017-2019)
- 3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Players (2017-2019)
- 3.2 Global Peptide Cancer Vaccine Revenue Market Share by Players
- 3.2.1 Global Peptide Cancer Vaccine Revenue by Players (2017-2019)
- 3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Players (2017-2019)
- 3.3 Global Peptide Cancer Vaccine Sale Price by Players
- 3.4 Global Peptide Cancer Vaccine Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Peptide Cancer Vaccine Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Peptide Cancer Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 Peptide Cancer Vaccine by Regions
- 4.1 Peptide Cancer Vaccine by Regions
- 4.1.1 Global Peptide Cancer Vaccine Consumption by Regions
- 4.1.2 Global Peptide Cancer Vaccine Value by Regions
- 4.2 Americas Peptide Cancer Vaccine Consumption Growth
- 4.3 APAC Peptide Cancer Vaccine Consumption Growth
- 4.4 Europe Peptide Cancer Vaccine Consumption Growth
- 4.5 Middle East & Africa Peptide Cancer Vaccine Consumption Growth
5 Americas
- 5.1 Americas Peptide Cancer Vaccine Consumption by Countries
- 5.1.1 Americas Peptide Cancer Vaccine Consumption by Countries (2014-2019)
- 5.1.2 Americas Peptide Cancer Vaccine Value by Countries (2014-2019)
- 5.2 Americas Peptide Cancer Vaccine Consumption by Type
- 5.3 Americas Peptide Cancer Vaccine Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Peptide Cancer Vaccine Consumption by Countries
- 6.1.1 APAC Peptide Cancer Vaccine Consumption by Countries (2014-2019)
- 6.1.2 APAC Peptide Cancer Vaccine Value by Countries (2014-2019)
- 6.2 APAC Peptide Cancer Vaccine Consumption by Type
- 6.3 APAC Peptide Cancer Vaccine Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Peptide Cancer Vaccine by Countries
- 7.1.1 Europe Peptide Cancer Vaccine Consumption by Countries (2014-2019)
- 7.1.2 Europe Peptide Cancer Vaccine Value by Countries (2014-2019)
- 7.2 Europe Peptide Cancer Vaccine Consumption by Type
- 7.3 Europe Peptide Cancer Vaccine Consumption by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Peptide Cancer Vaccine by Countries
- 8.1.1 Middle East & Africa Peptide Cancer Vaccine Consumption by Countries (2014-2019)
- 8.1.2 Middle East & Africa Peptide Cancer Vaccine Value by Countries (2014-2019)
- 8.2 Middle East & Africa Peptide Cancer Vaccine Consumption by Type
- 8.3 Middle East & Africa Peptide Cancer Vaccine Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Marketing, Distributors and Customer
- 10.1 Sales Channel
- 10.1.1 Direct Channels
- 10.1.2 Indirect Channels
- 10.2 Peptide Cancer Vaccine Distributors
- 10.3 Peptide Cancer Vaccine Customer
11 Global Peptide Cancer Vaccine Market Forecast
- 11.1 Global Peptide Cancer Vaccine Consumption Forecast (2019-2024)
- 11.2 Global Peptide Cancer Vaccine Forecast by Regions
- 11.2.1 Global Peptide Cancer Vaccine Forecast by Regions (2019-2024)
- 11.2.2 Global Peptide Cancer Vaccine Value Forecast by Regions (2019-2024)
- 11.2.3 Americas Consumption Forecast
- 11.2.4 APAC Consumption Forecast
- 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
- 11.3.1 United States Market Forecast
- 11.3.2 Canada Market Forecast
- 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
- 11.4.1 China Market Forecast
- 11.4.2 Japan Market Forecast
- 11.4.3 Korea Market Forecast
- 11.4.4 Southeast Asia Market Forecast
- 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
- 11.6.1 Egypt Market Forecast
- 11.6.2 South Africa Market Forecast
- 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast
- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Peptide Cancer Vaccine Forecast by Type
- 11.8 Global Peptide Cancer Vaccine Forecast by Application
12 Key Players Analysis
- 12.1 TapImmune
- 12.1.1 Company Details
- 12.1.2 Peptide Cancer Vaccine Product Offered
- 12.1.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.1.4 Main Business Overview
- 12.1.5 TapImmune News
- 12.2 BrightPath Biotherapeutics
- 12.2.1 Company Details
- 12.2.2 Peptide Cancer Vaccine Product Offered
- 12.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.2.4 Main Business Overview
- 12.2.5 BrightPath Biotherapeutics News
- 12.3 Ultimovacs
- 12.3.1 Company Details
- 12.3.2 Peptide Cancer Vaccine Product Offered
- 12.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.3.4 Main Business Overview
- 12.3.5 Ultimovacs News
- 12.4 Sellas
- 12.4.1 Company Details
- 12.4.2 Peptide Cancer Vaccine Product Offered
- 12.4.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.4.4 Main Business Overview
- 12.4.5 Sellas News
- 12.5 Boston Biomedical
- 12.5.1 Company Details
- 12.5.2 Peptide Cancer Vaccine Product Offered
- 12.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.5.4 Main Business Overview
- 12.5.5 Boston Biomedical News
- 12.6 Imugene
- 12.6.1 Company Details
- 12.6.2 Peptide Cancer Vaccine Product Offered
- 12.6.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.6.4 Main Business Overview
- 12.6.5 Imugene News
- 12.7 VAXON Biotech
- 12.7.1 Company Details
- 12.7.2 Peptide Cancer Vaccine Product Offered
- 12.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.7.4 Main Business Overview
- 12.7.5 VAXON Biotech News
- 12.8 Generex Biotechnology
- 12.8.1 Company Details
- 12.8.2 Peptide Cancer Vaccine Product Offered
- 12.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.8.4 Main Business Overview
- 12.8.5 Generex Biotechnology News
- 12.9 ISA Pharmaceuticals
- 12.9.1 Company Details
- 12.9.2 Peptide Cancer Vaccine Product Offered
- 12.9.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.9.4 Main Business Overview
- 12.9.5 ISA Pharmaceuticals News
- 12.10 OncoTherapy Science
- 12.10.1 Company Details
- 12.10.2 Peptide Cancer Vaccine Product Offered
- 12.10.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2017-2019)
- 12.10.4 Main Business Overview
- 12.10.5 OncoTherapy Science News
- 12.11 Immatics
13 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Peptide Cancer Vaccine . Industry analysis & Market Report on Peptide Cancer Vaccine is a syndicated market report, published as Global Peptide Cancer Vaccine Market Growth 2019-2024. It is complete Research Study and Industry Analysis of Peptide Cancer Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
